Human papillomavirus vaccine - ARTES/BioSun Pharmed

Drug Profile

Human papillomavirus vaccine - ARTES/BioSun Pharmed

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator ARTES Biotechnology
  • Developer ARTES Biotechnology; BioSun Pharmed
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Human papillomavirus infections

Most Recent Events

  • 04 Nov 2016 ARTES and BioSun agree to co-develop human papillomavirus (HPV) vaccine in Iran for Human papillomavirus infections
  • 04 Nov 2016 Early research in Human papillomavirus infections (Prevention) in Iran (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top